Form 8-K - Current report:
SEC Accession No. 0000950170-24-134064
Filing Date
2024-12-06
Accepted
2024-12-06 16:03:58
Documents
16
Period of Report
2024-12-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K revb-20241203.htm   iXBRL 8-K 59218
2 EX-4.1 revb-ex4_1.htm EX-4.1 178063
3 EX-4.2 revb-ex4_2.htm EX-4.2 209107
4 EX-10.1 revb-ex10_1.htm EX-10.1 126467
5 EX-99.1 revb-ex99_1.htm EX-99.1 20461
6 GRAPHIC img220778470_0.jpg GRAPHIC 18521
  Complete submission text file 0000950170-24-134064.txt   865658

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT revb-20241203.xsd EX-101.SCH 49101
18 EXTRACTED XBRL INSTANCE DOCUMENT revb-20241203_htm.xml XML 6943
Mailing Address 4660 LAJOLLA VILLAGE DRIVE SUITE 100 SAN DIEGO CA 92122
Business Address 4660 LAJOLLA VILLAGE DRIVE SUITE 100 SAN DIEGO CA 92122 650-800-3717
REVELATION BIOSCIENCES, INC. (Filer) CIK: 0001810560 (see all company filings)

EIN.: 843898466 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39603 | Film No.: 241532231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)